Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics Incorporated - Common Stock (NQ: PRLD )

1.300 +0.412 (+46.40%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Prelude Therapeutics Incorporated - Common Stock

< Previous 1 2 Next >
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST) 
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitor 
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Announces $25 Million Private Placement
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
From AbCellera Biologics Inc.
Via Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader 
From Prelude Therapeutics, Inc.; AbCellera
Via GlobeNewswire
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics To Participate in Jefferies Healthcare Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Announces Pricing of Public Offering
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Announces Launch of Proposed Public Offering
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
Eight Abstracts Demonstrate Progress of Prelude’s Differentiated Pipeline 
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.